Przejdź do zawartości
Merck

Human nuclear hormone receptor activity contributes to malaria parasite liver stage development.

Cell chemical biology (2023-05-13)
Nimisha Mittal, Chadwick Davis, Peter McLean, Jaeson Calla, Karla P Godinez-Macias, Alison Gardner, David Healey, Pamela Orjuela-Sanchez, Sabine Ottilie, Yolanda Chong, Christopher Gibson, Elizabeth A Winzeler
ABSTRAKT

Chemical genetic approaches have had a transformative impact on discovery of drug targets for malaria but have primarily been used for parasite targets. To identify human pathways required for intrahepatic development of parasite, we implemented multiplex cytological profiling of malaria infected hepatocytes treated with liver stage active compounds. Some compounds, including MMV1088447 and MMV1346624, exhibited profiles similar to cells treated with nuclear hormone receptor (NHR) agonist/antagonists. siRNAs targeting human NHRs, or their signaling partners identified eight genes that were critical for Plasmodium berghei infection. Knockdown of NR1D2, a host NHR, significantly impaired parasite growth by downregulation of host lipid metabolism. Importantly, treatment with MMV1088447 and MMV1346624 but not other antimalarials, phenocopied the lipid metabolism defect of NR1D2 knockdown. Our data underlines the use of high-content imaging for host-cellular pathway deconvolution, highlights host lipid metabolism as a drug-able human pathway and provides new chemical biology tools for studying host-parasite interactions.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-NR1D2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Roche
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial